Cargando…

Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study

BACKGROUND: As clinical tests, such as gait speed, require nervous system integrity to be performed properly, sarcopenia shares features with neurological diseases. Neurofilament light chains (NF-L) are now used as a blood-biomarker of neuronal damage, and its expression might be altered in sarcopen...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladang, Aurélie, Kovacs, Stéphanie, Lengelé, Laetitia, Locquet, Médéa, Beaudart, Charlotte, Reginster, Jean-Yves, Bruyère, Olivier, Cavalier, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520189/
https://www.ncbi.nlm.nih.gov/pubmed/37581861
http://dx.doi.org/10.1007/s40520-023-02521-9
_version_ 1785109860306649088
author Ladang, Aurélie
Kovacs, Stéphanie
Lengelé, Laetitia
Locquet, Médéa
Beaudart, Charlotte
Reginster, Jean-Yves
Bruyère, Olivier
Cavalier, Etienne
author_facet Ladang, Aurélie
Kovacs, Stéphanie
Lengelé, Laetitia
Locquet, Médéa
Beaudart, Charlotte
Reginster, Jean-Yves
Bruyère, Olivier
Cavalier, Etienne
author_sort Ladang, Aurélie
collection PubMed
description BACKGROUND: As clinical tests, such as gait speed, require nervous system integrity to be performed properly, sarcopenia shares features with neurological diseases. Neurofilament light chains (NF-L) are now used as a blood-biomarker of neuronal damage, and its expression might be altered in sarcopenia. We aimed to assess NF-L concentrations in a large cohort of older individuals screened for sarcopenia. METHODS: The SarcoPhAge cohort is a Belgian cohort of 534 community-dwelling older adults with an ongoing 10-year follow-up. Sarcopenia diagnosis was established at inclusion according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Muscle strength was evaluated with a hydraulic hand dynamometer, appendicular lean mass by Dual-Energy X-ray Absorptiometry (DXA) and physical performance by the Short Physical Performance Battery (SPPB). NF-L was measured on all available sera collected at the time of inclusion (n = 409) using SiMoA technology (Quanterix°). RESULTS: In the multivariate model, NF-L was associated with performance tests such as gait speed (p < 0.0001) and SPPB scores (p = 0.0004). An association was also observed with muscle strength (p = 0.0123) and lean mass (p = 0.0279). In the logistic regression model, NF-L was an independent predictor of severe sarcopenia (p = 0.0338; OR = 20.0; 95% CI 1.39–287.7) with satisfactory diagnostic accuracy (AUC: 0.828) and subjects with an SPPB score ≤ 8 had higher odds of having increased NF-L (p < 0.0001; OR = 23.9; 95% CI 5.5–104). CONCLUSIONS: These data highlight the potential for using NF-L to investigate the pathophysiology of sarcopenia severity and the neurological features associated with performance tests. However, these results need to be confirmed with other cohorts in different settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40520-023-02521-9.
format Online
Article
Text
id pubmed-10520189
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-105201892023-09-27 Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study Ladang, Aurélie Kovacs, Stéphanie Lengelé, Laetitia Locquet, Médéa Beaudart, Charlotte Reginster, Jean-Yves Bruyère, Olivier Cavalier, Etienne Aging Clin Exp Res Original Article BACKGROUND: As clinical tests, such as gait speed, require nervous system integrity to be performed properly, sarcopenia shares features with neurological diseases. Neurofilament light chains (NF-L) are now used as a blood-biomarker of neuronal damage, and its expression might be altered in sarcopenia. We aimed to assess NF-L concentrations in a large cohort of older individuals screened for sarcopenia. METHODS: The SarcoPhAge cohort is a Belgian cohort of 534 community-dwelling older adults with an ongoing 10-year follow-up. Sarcopenia diagnosis was established at inclusion according to the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Muscle strength was evaluated with a hydraulic hand dynamometer, appendicular lean mass by Dual-Energy X-ray Absorptiometry (DXA) and physical performance by the Short Physical Performance Battery (SPPB). NF-L was measured on all available sera collected at the time of inclusion (n = 409) using SiMoA technology (Quanterix°). RESULTS: In the multivariate model, NF-L was associated with performance tests such as gait speed (p < 0.0001) and SPPB scores (p = 0.0004). An association was also observed with muscle strength (p = 0.0123) and lean mass (p = 0.0279). In the logistic regression model, NF-L was an independent predictor of severe sarcopenia (p = 0.0338; OR = 20.0; 95% CI 1.39–287.7) with satisfactory diagnostic accuracy (AUC: 0.828) and subjects with an SPPB score ≤ 8 had higher odds of having increased NF-L (p < 0.0001; OR = 23.9; 95% CI 5.5–104). CONCLUSIONS: These data highlight the potential for using NF-L to investigate the pathophysiology of sarcopenia severity and the neurological features associated with performance tests. However, these results need to be confirmed with other cohorts in different settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40520-023-02521-9. Springer International Publishing 2023-08-15 2023 /pmc/articles/PMC10520189/ /pubmed/37581861 http://dx.doi.org/10.1007/s40520-023-02521-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Ladang, Aurélie
Kovacs, Stéphanie
Lengelé, Laetitia
Locquet, Médéa
Beaudart, Charlotte
Reginster, Jean-Yves
Bruyère, Olivier
Cavalier, Etienne
Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study
title Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study
title_full Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study
title_fullStr Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study
title_full_unstemmed Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study
title_short Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study
title_sort neurofilament-light chains (nf-l), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the sarcophage study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10520189/
https://www.ncbi.nlm.nih.gov/pubmed/37581861
http://dx.doi.org/10.1007/s40520-023-02521-9
work_keys_str_mv AT ladangaurelie neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT kovacsstephanie neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT lengelelaetitia neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT locquetmedea neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT beaudartcharlotte neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT reginsterjeanyves neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT bruyereolivier neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy
AT cavalieretienne neurofilamentlightchainsnflabiomarkerofneuronaldamageisincreasedinpatientswithseveresarcopeniaresultsofthesarcophagestudy